Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01505673 · ClinicalTrials.gov registry record · Phase 4
Adding Liraglutide to High Dose Insulin: Breaking the Cycle
A Phase 4 study of Obesity and Type 2 Diabetes Mellitus, sponsored by Ildiko Lingvay.
- Completed
- Registry status
- Phase 4
- Development phase
- 71
- Enrollment target
- 1
- Study location
NCT01505673: Completed Phase 4 study of Obesity and Type 2 Diabetes Mellitus, sponsored by Ildiko Lingvay.
NCT01505673 is a Phase 4 study of Obesity and Type 2 Diabetes Mellitus that has completed, run by Ildiko Lingvay. The registered enrollment target is 71 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01505673, a Phase 4 study of Obesity and Type 2 Diabetes Mellitus, has completed, sponsored by Ildiko Lingvay.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 71 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate whether the addition of liraglutide 1.8 mg/day to a high-dose insulin regimen (\>1.8 units/kg/day) in patients with uncontrolled (HbA1c \>7.5%) type 2 diabetes mellitus will improve blood sugar control. It also evaluates the effect of liraglutide on liver and pancreatic fat content, explores the mechanism of blood sugar improvement by assessing weight and pancreatic hormone release, and assesses blood pressure, lipid profile, and liver function. Finally it will look at patient quality of life and safety.
Primary Outcome
HbA1c (%)
Conditions Studied
Interventions
- DRUG Saline
- DRUG Liraglutide
Study Locations (1)
Texas
- UT Southwestern - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 71 participants |
| Start Date | 2012-01 |
| Est. Completion | 2016-06 |
| Phase | Phase 4 |
What the finished NCT01505673 record still lists
NCT01505673 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (91% lower).
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Saline is the first listed.
NCT01505673 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01505673 about?
NCT01505673 is a clinical study titled "Adding Liraglutide to High Dose Insulin: Breaking the Cycle". The purpose of this study is to evaluate whether the addition of liraglutide 1.8 mg/day to a high-dose insulin regimen (\>1.8 units/kg/day) in patients with uncontrolled (HbA1c \>7.5%) type 2 diabetes mellitus will improve blood sugar control. It also evaluates the effect of liraglutide on liver an...
What is the current status of trial NCT01505673?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 71 participants. The study started on 2012-01. Estimated completion is 2016-06.
What conditions does trial NCT01505673 study?
This clinical trial studies the following conditions: Obesity, Type 2 Diabetes Mellitus.
What interventions are being tested in trial NCT01505673?
The interventions under investigation include: Saline (DRUG), Liraglutide (DRUG).
Who is sponsoring clinical trial NCT01505673?
This trial is sponsored by Ildiko Lingvay, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01505673 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01505673's enrollment target sits among peer trials
71 593rd of 1053 higher than 460 of 1,053 other Obesity trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obesity trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
RECRUITING · Phase 4
-
Phenotype-Tailored Lifestyle Intervention for Obesity: A Randomized Trial
RECRUITING · Phase 4
-
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
RECRUITING · Phase 4
-
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
RECRUITING · Phase 4
-
Fibrosis Lessens After Metabolic Surgery
RECRUITING · Phase 4
-
Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05452889 · 71 participants · Early Phase 1
PET Image in PAH Patients
- NCT05766943 · 71 participants · NA
Reduction of Myopotential Interference With Smart Pass in S-ICD Patients
- NCT06229678 · 71 participants · Early Phase 1
Ketones, SGLT2, HFrEF
- NCT06377566 · 71 participants · Phase 2
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia